SAN DIEGO, Oct. 16, 2024 /PRNewswire/ -- Kintara Therapeutics, Inc. ("Kintara") (NASDAQ: KTRA), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, today ...
WESTMINSTER, Colo., Aug. 23, 2024 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (ABIO) (“ARCA”) today announced that its Board of Directors (the “Board”) has approved a reverse stock split of ARCA’s common ...
FRAMINGHAM, Mass., Jan. 17, 2023 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), a marketer and developer of novel self-assembling wound care and biosurgical ...
STAMFORD, Conn., April 14, 2025 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA) (the “Company”), today announced that its Board of Directors (the “Board”) has approved a 1-for-3 reverse ...
The reverse stock split will affect all stockholders uniformly and will not alter any stockholder's percentage interest in Kintara's equity, except to the extent that the reverse stock split results ...
SAN DIEGO, Oct. 16, 2024 /PRNewswire/ -- Kintara Therapeutics, Inc. ("Kintara") (NASDAQ: KTRA), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, today ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback